pet amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to alzheimers disease宠物淀粉样蛋白成像作为早期诊断和识别工具患者发展为阿尔茨海默氏症的风险.pdfVIP

Pontecorvo and Mintun Alzheimer’s Research Therapy 2011, 3:11 /content/3/2/11 R E V I E W PET amyloid imaging as a tool for early diagnosis and identifying patients at risk for progression to Alzheimer’s disease Michael J Pontecorvo* and Mark A Mintun Nevertheless, there remains both room and a need for Abstract improvement in diagnostic accuracy. Up to 20% of Current theory suggests that β-amyloid accumulation subjects clinically diagnosed with AD do not have AD may be an early step in the cascade that leads to pathology at autopsy [4-6], a percentage that is essentially cognitive impairment in Alzheimer’s disease. β-Amyloid unchanged from the estimate in the 1984 consensus targeted positron emission tomography (PET) imaging publication [1]. In addition, under-diagnosis in the potentially provides a direct, relatively noninvasive commu nity setting is signifi cant. Approximately 10% of estimate of brain β-amyloid burden. This has recently community-dwelling elderly have undiagnosed dementia been supported by demonstration that amyloid [7,8] and community physicians may fail to diagnose up plaque binding on PET was strongly correlated with to 33% of individuals with mild dementia [8]. brain β-amyloid burden at autopsy. Additionally, there Perhaps the biggest limitation in current practice is a is growing consensus that PET imaging can identify reliance on the presentation and progression of subjects with elevated β-amyloid burden, even at early symptoms to identi